The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics-Reference-Cited by-同舟云学术

The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics

Published:2015-12 Issue:12 Volume:20 Page:1439-1450
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Trusheim Mark R.,Berndt Ernst R.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference44 articles.

1. Remicade (infliximab) Label, Revised: January 2015;US Food and Drug Administration,2015

2. Pathologic complete response: understanding the subtleties;Helwick;ASCO Post 5,2014

3. Statin drugs given for 5 years for heart disease prevention (with known heart disease);Newman;TheNNT.com,2013

4. The JUPITER Trial: results, controversies and implications for prevention;Ridker;Circ. Cardiovasc. Quality Outcomes,2009

5. Evaluating Statin Drugs to Treat: High Cholesterol and Heart Disease, Comparing Effectiveness, Safety and Price, Consumer Reports;Consumer Reports,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TherapyPal: Towards a Privacy-Preserving Companion Diagnostic Tool based on Digital Symptomatic Phenotyping;Proceedings of the 29th Annual International Conference on Mobile Computing and Networking;2023-10-02

2. Immunohistochemistry: Roche Tissue Diagnostics Perspective;Handbook of Practical Immunohistochemistry;2022

3. Biomarker Panels and Contemporary Practice in Clinical Trials of Personalized Medicine;Biomarkers of the Tumor Microenvironment;2022

4. The Health Economics of Personalized Precision Medicine;Advancing Healthcare Through Personalized Medicine;2021

5. Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice;Journal of Personalized Medicine;2020-06-29